Metabolomics is the worldwide assessment and confirmation of endogenous small-molecule biochemicals (metabolites) within a biologic system. It is one of the "omic" sciences in systems biology. The metabolism of cancer cells is dysregulated to meet the demands of uncontrolled proliferation. This rewiring of cellular metabolism produces distinct metabolic phenotypes that can be exploited for earlier cancer detection, patient selection techniques for clinical trials, and/or treatment response biomarkers. Metabolomics aims to use cancer’s metabolic signature to estimate disease risk, detect cancer earlier, diagnose particular disease subtypes, and track treatment outcomes. In principle, metabolomics could aid in the rational selection of targeted medicines to meet cancer’s metabolic requirements.
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China